Genitourinary cancers are known for some of the leading causes of global mortality. This includes prostate cancer which is the most common malignancy in men worldwide and has more than 48,000 cases of diagnosis each year. Another genitourinary is renal cell carcinoma, known as the most common form of kidney cancer with various histological subtypes and low prognosis. Bladder cancer has also been confirmed as the 10th most common cancer with over 90% of bladder cancer cases as urothelial carcinoma.
There has been significant progress towards the treatment of patients with genitourinary cancers. For example, immunotherapy serves as a promising strategy which improves the prognosis of prostate cancer and renal cell carcinoma patients. However, the molecular mechanisms remain to be studied further and therefore, there is an urgent requirement for the identification of novel biomarkers to improve the survival rate and prognosis of genitourinary cancers. The study of biomarkers has become a major focus in research primarily focusing on how they can help the responses to drug resistance and ineffective treatments. The impact of biomarkers in selecting potentially responsive patients improves outcomes, and reduces costs related to ineffective treatments and, most importantly, significantly improves patient’s quality of life.
This Research Topic aims to explore the identification of biomarkers in helping the prognosis in genitourinary cancers. Topics of interest include:
-Biomarkers identified in prostate, bladder and renal cancers
-Emerging prognostic and predictive biomarkers
-Identification of biomarkers associated with immune status
-Impact of biomarker discovery in the prognosis and epidemiology of genitourinary cancers
We welcome the submission of Original Research, Review, Mini-Review, and Clinical Trial articles covering, but not limited to, the above topics.
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
Genitourinary cancers are known for some of the leading causes of global mortality. This includes prostate cancer which is the most common malignancy in men worldwide and has more than 48,000 cases of diagnosis each year. Another genitourinary is renal cell carcinoma, known as the most common form of kidney cancer with various histological subtypes and low prognosis. Bladder cancer has also been confirmed as the 10th most common cancer with over 90% of bladder cancer cases as urothelial carcinoma.
There has been significant progress towards the treatment of patients with genitourinary cancers. For example, immunotherapy serves as a promising strategy which improves the prognosis of prostate cancer and renal cell carcinoma patients. However, the molecular mechanisms remain to be studied further and therefore, there is an urgent requirement for the identification of novel biomarkers to improve the survival rate and prognosis of genitourinary cancers. The study of biomarkers has become a major focus in research primarily focusing on how they can help the responses to drug resistance and ineffective treatments. The impact of biomarkers in selecting potentially responsive patients improves outcomes, and reduces costs related to ineffective treatments and, most importantly, significantly improves patient’s quality of life.
This Research Topic aims to explore the identification of biomarkers in helping the prognosis in genitourinary cancers. Topics of interest include:
-Biomarkers identified in prostate, bladder and renal cancers
-Emerging prognostic and predictive biomarkers
-Identification of biomarkers associated with immune status
-Impact of biomarker discovery in the prognosis and epidemiology of genitourinary cancers
We welcome the submission of Original Research, Review, Mini-Review, and Clinical Trial articles covering, but not limited to, the above topics.
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
